Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 2/20 | 0.34 |
| ▸ | DUT | P33316 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5350935 | 1.00 | TK1 (0.41) | TK1CTSKADRB2ADRB1ADRB3 | |
| SCHEMBL9174666 | 0.85 | TK1 (0.43) | TK1CTSKALDH1A1 | |
| SCHEMBL10463726 | 0.84 | TK1 (0.43) | TK1CTSKADRB2ADRB1ADRB3 | |
| SCHEMBL9173106 | 0.84 | TK1 (0.43) | TK1CTSKADRB2ADRB1ADRB3 | |
| SCHEMBL5370796 | 0.83 | TK1 (0.41) | TK1CTSKADRB2ADRB1ADRB3 | |
| SCHEMBL3963389 | 0.83 | TK1 (0.41) | TK1CTSKADRB2ADRB1ADRB3 | |
| SCHEMBL3837132 | 0.81 | TK1 (0.45) | TK1CTSKADRB2ADRB1ADRB3 | |
| SCHEMBL5354077 | 0.81 | TK1 (0.45) | TK1CTSKADRB2ADRB1ADRB3 | |
| SCHEMBL4668660 | 0.80 | CYP2D6 (0.40) | CTSKCYP2C19KDM4EALDH1A1TDP1 | |
| SCHEMBL6482683 | 0.80 | PPARA (0.51) | ADRB2ADRB1ADRB3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478650-B1 | NOVEL BORONATE ESTERS | BIOCON LTD (IN) | 2009-09-30 | — | — | EP | disclosed |
| EP-1478650-A4 | NOVEL BORONATE ESTERS | BIOCON LTD (IN) | 2008-02-13 | — | — | EP | disclosed |
| US-7301046-B2 | Boronate esters | BIOCON LIMITED (IN) | 2007-11-27 | — | — | US | disclosed |
| US-7238826-B2 | Boronate esters | BIOCON LIMITED (IN) | 2007-07-03 | — | — | US | disclosed |
| US-20060040898-A1 | Novel boronate esters | BIOCON LIMITED (IN) | 2006-02-23 | — | — | US | disclosed |
| US-20050154213-A1 | Novel boronate esters | BIOCON LIMITED (IN) | 2005-07-14 | — | — | US | disclosed |
| WO-2004113314-A1 | NOVEL BORONATE ESTERS | BIOCON LIMITED (IN) | 2004-12-29 | — | — | WO | disclosed |
| EP-1478650-A1 | NOVEL BORONATE ESTERS | Biocon Limited (IN) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003070733-A1 | NOVEL BORONATE ESTERS | BIOCON LIMITED (IN) | 2003-08-28 | — | — | WO | disclosed |
| EP-0363934-B1 | Process for the preparation of 7-substituted-hept-6-enoic and -heptanoic acids and derivatives thereof | SANDOZ AG (CH) | 1993-12-29 | — | — | EP | disclosed |
| EP-0562643-A2 | 7-Substituted-hept-6-enoic and -heptanoic acids and derivatives thereof | SANDOZ AG (CH) | 1993-09-29 | — | — | EP | disclosed |
| WO-1990003962-A1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-HEPT-6-ENOIC AND -HEPTANOIC ACIDS AND DERIVATIVES AND INTERMEDIATES THEREOF | SANDOZ AG (CH) | 1990-04-19 | — | — | WO | disclosed |
| EP-0363934-A1 | Process for the preparation of 7-substituted-hept-6-enoic and -heptanoic acids and derivatives thereof | SANDOZ AG (CH) | 1990-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040898-A1 | Novel boronate esters | HMGCR, BLVRB, COASY | TK1 1347/4885CTSK 1006/4885ADRB2 3207/4885 |
| US-20050154213-A1 | Novel boronate esters | HMGCR, BLVRB, COASY | TK1 1388/4885CTSK 1041/4885ADRB2 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.